Gondolabio

Gondolabio company information, Employees & Contact Information

Explore related pages

Related company profiles:

GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

Company Details

Employees
46
Address
3160 Porter Dr, Palo Alto,california 94304,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Palo Alto, California
Looking for a particular Gondolabio employee's phone or email?

Gondolabio Questions

News

GondolaBio Receives U.S. FDA Orphan Drug and Fast Track Designations for PORT-77 for the Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) - Yahoo Finance

GondolaBio Receives U.S. FDA Orphan Drug and Fast Track Designations for PORT-77 for the Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) Yahoo Finance

GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases - Business Wire

GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases Business Wire

BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture - BioSpace

BridgeBio Launches GondolaBio With $300M, Transfers Programs to Joint Venture BioSpace

BridgeBio launches another offshoot with $300M and early genetic disease programs - Fierce Biotech

BridgeBio launches another offshoot with $300M and early genetic disease programs Fierce Biotech

BridgeBio sends rare disease drugs to new company - BioPharma Dive

BridgeBio sends rare disease drugs to new company BioPharma Dive

N-Lorem, Gondolabio to advance ASO treatment for rare diseases - AADC News

N-Lorem, Gondolabio to advance ASO treatment for rare diseases AADC News

BridgeBio forms another offshoot with $300M in commitments - Endpoints News

BridgeBio forms another offshoot with $300M in commitments Endpoints News

BridgeBio launches another new company, GondolaBio - The Pharma Letter

BridgeBio launches another new company, GondolaBio The Pharma Letter

Top Gondolabio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant